MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor
MSD's bet on targeting RAS comes amid the industry buzz around the approval of Revolution's OS-doubling pancreatic cancer drug, Rasonque.
MSD's bet on targeting RAS comes amid the industry buzz around the approval of Revolution's OS-doubling pancreatic cancer drug, Rasonque.